Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason M Pogue

Showing results (71-80 of 167) with videos related to

Pageof 17
Sort By:
Antimicrobial Agents and Chemotherapy|July 1, 2015
Nephrotoxicity comparison of two commercially available generic vancomycin productsJesse D Sutton, Ryan P Mynatt, Keith S Kaye, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2024
The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?Samuel L Aitken, Virginia M Pierce, Jason M Pogue, et al.
Open Forum Infectious Diseases|September 3, 2020
Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics TestsLaura N Cwengros, Ryan P Mynatt, Tristan T Timbrook, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 9, 2022
Pharmacists as important prescribers of coronavirus disease 2019 (COVID-19) antiviralsMonica V Mahoney, Hita Bhagat, Robbie Christian, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2024
A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosaWalaiporn Wangchinda, Keith S Kaye, Twisha S Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 9, 2011
Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health systemJason M Pogue, Jiha Lee, Dror Marchaim, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2018
An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two CitiesJason M Pogue, Emily L Heil, Paul Lephart, et al.
Antimicrobial Agents and Chemotherapy|December 19, 2018
The Hypothetical Impact of Accelerate Pheno on Time to Effective Therapy and Time to Definitive Therapy for Bloodstream Infections Due to Drug-Resistant Gram-Negative BacilliOryan Henig, Keith S Kaye, Suganya Chandramohan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2014
Bringing the "power" to Cerner's PowerChart for antimicrobial stewardshipJason M Pogue, Brian A Potoski, Michael Postelnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2026
Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled analysis from two pivotal Phase 3 studiesAmanda J Sheets, Jeremy Dennison, Jason M Pogue, et al.
Pageof 17

Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
Antimicrobial Agents and Chemotherapy|July 1, 2015
Nephrotoxicity comparison of two commercially available generic vancomycin productsJesse D Sutton, Ryan P Mynatt, Keith S Kaye, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2024
The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?Samuel L Aitken, Virginia M Pierce, Jason M Pogue, et al.
Open Forum Infectious Diseases|September 3, 2020
Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics TestsLaura N Cwengros, Ryan P Mynatt, Tristan T Timbrook, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 9, 2022
Pharmacists as important prescribers of coronavirus disease 2019 (COVID-19) antiviralsMonica V Mahoney, Hita Bhagat, Robbie Christian, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2024
A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosaWalaiporn Wangchinda, Keith S Kaye, Twisha S Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 9, 2011
Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health systemJason M Pogue, Jiha Lee, Dror Marchaim, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2018
An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two CitiesJason M Pogue, Emily L Heil, Paul Lephart, et al.
Antimicrobial Agents and Chemotherapy|December 19, 2018
The Hypothetical Impact of Accelerate Pheno on Time to Effective Therapy and Time to Definitive Therapy for Bloodstream Infections Due to Drug-Resistant Gram-Negative BacilliOryan Henig, Keith S Kaye, Suganya Chandramohan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2014
Bringing the "power" to Cerner's PowerChart for antimicrobial stewardshipJason M Pogue, Brian A Potoski, Michael Postelnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2026
Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled analysis from two pivotal Phase 3 studiesAmanda J Sheets, Jeremy Dennison, Jason M Pogue, et al.
Pageof 17